Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pharvaris N.V.
(NQ:
PHVS
)
18.00
+0.70 (+4.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
453,119
Open
17.61
Bid (Size)
17.10 (1)
Ask (Size)
23.28 (1)
Prev. Close
17.30
Today's Range
17.47 - 19.11
52wk Range
15.00 - 33.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
August 28, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024
August 14, 2024
PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-30.42%
-30.42%
1 Month
+12.92%
+12.92%
3 Month
+1.64%
+1.64%
6 Month
-22.51%
-22.51%
1 Year
-15.57%
-15.57%
More News
Read More
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Via
Investor's Business Daily
Analyst Expectations for Pharvaris's Future
December 07, 2023
Via
Benzinga
Pharvaris Announces Annual Meeting of Shareholders
June 11, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
June 04, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
May 13, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024
May 08, 2024
Via
InvestorPlace
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023
April 10, 2024
Via
InvestorPlace
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 10, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
April 10, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
April 04, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
March 18, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
March 06, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
March 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
February 22, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Extraordinary Meeting of Shareholders
February 16, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present at the WSAAI Annual Meeting 2024
January 26, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision
January 22, 2024
Via
Investor's Business Daily
Exposures
Product Safety
FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps
January 22, 2024
Via
Benzinga
Exposures
Product Safety
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
January 22, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
January 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
December 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.